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Prognostic Significance of Tissue Polypeptide- 
specific Antigen (TPS) in Patients With Advanced 
Non-small Cell Lung Cancer 
A. van der Gaast, C.H.H. Schoenmakers, T.C. Kok, B.G. Blijenberg, 
W.C.J. Hop and T.A.W. Splinter 
In this study, we evaluated the prognostic value of the tumour marker, tissue polypeptide-specific antigen (TPS), 
in 203 patients with non-small cell lung cancer (NSCLC), and related this to several other known prognostic 
factors. TPS was signiticantly correlated with lactate dehydrogenase (LDH), y-glutamyltranspeptidase and 
alkaline phosphatase, and the median level of TPS in patients with stage 4 disease was significantly higher as 
compared to stage 3A and 3B disease. In the univariate analysis, performance status, stage of disease, LDH, 
alkaline phosphatase, a ;histology of undifferentiated large cell carcinoma and TPS all had a statistically significant 
association with survivatl. Multivariate analysis showed that stage of disease, performance status, histology and 
TPS were the most important prognostic factors. TPS has prognostic significance for survival in patients with 
advanced NSCLC, independent from performance status and stage of disease. 
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INTRODUCTION 
THE TUMOUR marker, tissue polypeptide antigen (TPA), is an 
insoluble and heat-labile tumour-associated antigen, which was 
tirst described by Bjorklund in 1957 [l]. It has been reported 
that TPA is produced durin,g the late S and G2 phase of the cell 
cycle, and is released during and immediately after mitosis 121. 
By monoclonal mapping of TPA, more than 30 epitopes have 
been recognised [I]. The &sue polypeptide-specific antigen 
(TPSTM) ELISA is an in vitro monoclonal enzyme-linked immu- 
nosorbent assay which has been developed for the measurement 
of the M3-specific epitope of TPA. This epitope is thought 
to constitute the critical TPA specificity as related to cell 
proliferation. However, immunohistochemical studies also dem- 
onstrate a similarity between localisation of TPS and various 
cytokeratins [3]. 
Reports on TPA in small cell lung cancer and non-small cell 
lung cancer (NSCLC) have indicated that raised TPA levels are 
associated with a shortened ourvival, that TPA levels are often 
correlated with stage, and that serial measurements of TPA may 
be useful in the detection of disease recurrence [C9]. However, 
such information is only scarce or not available for TPS . 
The aim of the present study was to evaluate the prognostic 
value for survival of TPS in patients with advanced NSCLC with 
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regard to stage of disease, performance status, age, gender, 
weight loss and some biochemical parameters such as lactate 
dehydrogenase (LDH), y-glutamyltranspeptidase and alkaline 
phosphatase. 
Patients 
PATIBNTS AND METHODS 
Serum samples were collected from 203 patients, on admit- 
tance to the Department of Medical Oncology, with histologi- 
cally-proven locally-advanced (stage 3A and 3B) and metastatic 
(stage 4) NSCLC. Serum samples of patients who presented 
with metastatic disease after previous local therapy (surgery or 
radiotherapy) were also included. The latter patients were 
categorised as having stage 4 disease. The samples were stored 
at -70°C until analysis. Patients were staged according to 
guidelines of the American Joint Committee on Cancer [lo]. 
Nodal status was confirmed histologically or cytologically by 
mediastinoscopy, mediastinotomy or thoracotomy for those 
patients with stage 3A disease. Treatment in these patients was 
diverse and consisted of radiotherapy, chemotherapy or only 
supportive care. 
Marker assessment-tke TPS assay 
TPS concentrations were measured with a TPS ELISA kit 
(BEKI Diagnostics AB, Bromma, Sweden) according to the 
manufacturer’s instructions. 
Statistical methods 
Differences between the medians of two groups were tested 
using Mann-Whitney’s test. P = 0.05 was considered the limit 
of significance. To obtain approximate normal distributions, 
TPS, LDH, alkaline phosphatase and y-glutamyltranspeptidase 
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Table 1. Patients’ characteristics 
No. of patients 
Total no. of patients 
Sex 
Female 
Male 
Age (years) 
range 
Performance status (ECOG) 
0 
1 
2 
3 
4 
Stage 
3A 
3B 
4 
Histology 
Adenocarcinoma 
Squamous cell carcinoma 
Large cell undifferentiated carcinoma 
Treatment 
Chemotherapy 
No chemotherapy 
203 
40 (20%) 
163 (80%) 
59 
29-81 
34 (17%) 
115 (58%) 
43 (21%) 
6 (3%) 
2 (1%) 
58 (29%) 
37 (18%) 
108 (53%) 
64 (32%) 
76 (37%) 
63 (31%) 
186 (92%) 
17 (8%) 
Missing data ECOG: n = 3. 
were logarithmically transformed before calculation of corre- 
lation coefficients. Survival was recorded from the date of the 
first TPS measurement to the date of death or last follow-up, 
and survival curves were calculated according to the method 
of Kaplan-Meier [ll]. Single variable survival analysis was 
calculated using the logrank test [ 121. Cox’s regression was used 
to simultaneously evaluate various prognostic factors [13]. 
RESULTS 
Patients’ characteristics are listed in Table 1. TPS could be 
determined in 203 patients. At the time of the analysis, the 
follow-up of 186 patients was complete. 17 patients were alive 
with a median follow-up of 22 months. The median survival for 
all patients was 8 months (range OS-90+). 
The median value of TPS for all patients was 144 U/l (range 
619208), for patients with adenocarcinoma 142 U/l (range 
2C19208), for patients with squamous cell carcinoma 169 U/1 
(range 62284), and for patients with large cell undifferentiated 
carcinoma 121 U/l (range 36-2866). There was no significant 
difference between the means of TPS for the various histologies. 
The median values for TPS according to stage are listed in Table 
2. 
The percentages of patients with an arbitrarily-chosen marker 
Table 2. TPS levels according to stage 
TPS Median Range 
Stage 3A (n = 58) 116* 6-19208 
Stage 3B (n = 37) 1W 25-666 
Stage 4 (n = 108) 144 34-7013 
Significantly different from stage 4:*P < 0.05, tF’ < 0.001. 
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Figure 1. Percentage of patients with a TPS level >lOO U/I for all 
patients and according to stage. 
Table 3. Correlation coefficients and significance level between lac- 
tate dehydrogenase (LDH), alkaline phosphatase, y-glutamyltrans- 
peptidase (YG r) and tissue polypeptide-specific antigen (TPS) 
LDH Alkaline 
phosphatase 
rGT 
TPS 0.50 (P < 0.001) 0.39 (P < 0.001) 0.37 (P cc 0.001) 
value above 100 U/l for all patients and according to stage are 
shown in Figure 1. 
Correlation of TPS and other biochemical parameters 
A significant correlation was found between serum TPS values 
and values of LDH, alkaline phosphatase and y-glutamyltrans- 
peptidase. The results are shown in Table 3. An example of a 
scatter diagram of TPS and LDH is depicted in Figure 2. 
Prognostic significance of TPS 
The results of the univariate analysis are summarised in 
Table 4. Performance status, stage of disease, LDH, alkaline 
phosphatase and TPS all had a statistically significant association 
with survival. Patients with a histology of undifferentiated large 
cell carcinoma had a significantly worse survival compared to 
patients with adenocarcinomas or squamous cell carcinomas. 
Age, weight loss, y-glutamyltranspeptidase and gender showed 
no statistically significant association with survival. 
Multivariate analysis (Table 5) revealed that stage of disease, 
performance status, histology and TPS were the most important 
prognostic factors. Addition of any of the other factors con- 
sidered did not significantly improve the fit of the model. 
The survival curves of patients based on their TPS levels are 
shown in Figure 3. 
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Figure 2. Scatter diagram of TPS versus LDH. 
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Figure 3. Survival curves of patients witb NSCLC based on their 
TPS levels. 
DISCUSSION 
The prognosis of patients with inoperable NSCLC is generally 
poor. Only a small subset of patients may have some benefit 
from chemotherapy [ 141. Well-established prognostic factors for 
survival in patients with inoperable NSCLC are stage of the 
disease and performance status [IS]. A number of other vari- 
ables, such as bone involvement, multiple metastatic site, gen- 
der, LDH, alkaline phosphatase and tumour markers, such as 
CEA, have also been reported to be related to prognosis. The 
reason that most of these variables are related to prognosis is 
most probably due to the fact that they give an indirect reflection 
of the total tumour load. 
In this study, we evaluated the prognostic significance of the 
recently-developed tumour marker TPS, and correlated it to 
some other clinical and biochemical parameters. We found that 
63% of 203 patients with advanced NSCLC had a serum level of 
TPS > 100 U/l. No sign&ant difference in TPS levels according 
to the histological type was found. The median TPS level found 
in patients with stage 4 disease was significantly higher as 
compared to stages 3A and 3B, while the latter did not sign& 
cantly differ from each other. 
In the univariate analysis, TPS, stage of the disease, perform- 
ance status, LDH, alkaline phosphatase and a histology of 
undifferentiated carcinoma compared to adenocarcinoma and 
squamous cell carcinoma were significant prognostic variables. 
However, in the multivariate analysis, only performance status, 
stage, histology and TPS remained as independent significant 
prognostic variables. 
The fact that in the multivariate analysis both TPS and stage 
were independent prognostic factors supports the suggestion 
that the prognostic information obtained by TPS is additional to 
the total tumour load. Madersbacher and colleagues [16] have 
demonstrated that TPS production by prostatic epithelial cells 
correlated with DNA synthesis, and TPS release did not depend 
on cell numbers. It is possible that the additional prognostic 
information obtained by TPS is due to the fact that TPS is 
thought to be an indicator of tumour proliferation. Although we 
investigated the M3 monoclonal antibody (TPS), which detects 
the M3-specific epitope that constitutes the critical TPA speci- 
ficity as related to cell proliferation, the results of this study are 
comparable to the results of the study of Buccheri and Ferrigno 
[9]. They demonstrated that TPA had prognostic significance in 
patients with lung cancer also independent from the stage of 
disease. 
In conclusion, TPS is an interesting tumour marker with 
frequently elevated levels in patients with advanced NSCLC and 
prognostic significance for survival, independent from perform- 
ance status and stage of the disease. Further investigations are 
warranted to explore the potential of this marker to determine 
choice of treatment, and whether or not this marker can be used 
for disease monitoring. 
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